These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 26882041)

  • 1. Impact of left ventricular ejection function on blood pressure-lowering therapy in hypertensive patients with coronary artery disease.
    Kikuchi N; Jujo K; Yamaguchi J; Ogawa H; Hagiwara N
    J Hypertens; 2016 May; 34(5):1011-8. PubMed ID: 26882041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of age on clinical outcomes of antihypertensive therapy in patients with hypertension and coronary artery disease: A sub-analysis of the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease.
    Kikuchi N; Ogawa H; Kawada-Watanabe E; Arashi H; Jujo K; Sekiguchi H; Yamaguchi J; Hagiwara N
    J Clin Hypertens (Greenwich); 2020 Jun; 22(6):1070-1079. PubMed ID: 32475050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of visit-to-visit variability and systolic blood pressure control on subsequent outcomes in hypertensive patients with coronary artery disease (from the HIJ-CREATE substudy).
    Arashi H; Ogawa H; Yamaguchi J; Kawada-Watanabe E; Hagiwara N
    Am J Cardiol; 2015 Jul; 116(2):236-42. PubMed ID: 25966826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of amlodipine + candesartan on cardiovascular events in hypertensive patients with coronary artery disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study).
    Yamaguchi J; Hagiwara N; Ogawa H; Koyanagi R; Kasanuki H; Takagi A; Mori F; Nagashima M; Yagi M;
    Am J Cardiol; 2010 Sep; 106(6):819-24. PubMed ID: 20816122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial.
    Kjeldsen SE; Berge E; Bangalore S; Messerli FH; Mancia G; Holzhauer B; Hua TA; Zappe D; Zanchetti A; Weber MA; Julius S
    Blood Press; 2016; 25(2):83-92. PubMed ID: 26511535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Could intensive anti-hypertensive therapy produce the "J-curve effect" in patients with coronary artery disease and hypertension after revascularization?
    Lu W
    Eur Rev Med Pharmacol Sci; 2016 Apr; 20(7):1350-5. PubMed ID: 27097958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin receptor blocker-based therapy and cardiovascular events in hypertensive patients with coronary artery disease and impaired renal function.
    Shiga T; Kasanuki H; Hagiwara N; Sumiyoshi T; Honda T; Haze K; Takagi A; Kawana M; Origasa H; Ogawa H;
    Blood Press; 2010 Dec; 19(6):359-65. PubMed ID: 20491606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of the combination of amlodipine and candesartan in hypertensive patients with coronary artery disease: a subanalysis of the HIJ-CREATE study.
    Koyanagi R; Hagiwara N; Yamaguchi J; Kawada-Watanabe E; Haruta S; Takagi A; Ogawa H;
    J Cardiol; 2013 Oct; 62(4):217-23. PubMed ID: 23778009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.
    Ogihara T; Fujimoto A; Nakao K; Saruta T;
    Expert Rev Cardiovasc Ther; 2008 Oct; 6(9):1195-201. PubMed ID: 18939907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal Blood Pressure in Patients With Coronary Artery Disease and Chronic Kidney Disease: HIJ-CREATE Substudy.
    Tanaka K; Jujo K; Yamaguchi J; Ogawa H; Hagiwara N
    Am J Med Sci; 2019 Sep; 358(3):219-226. PubMed ID: 31324360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality implications of lower DBP with lower achieved systolic pressures in coronary artery disease: long-term mortality results from the INternational VErapamil-trandolapril STudy US cohort.
    Wokhlu A; Smith SM; Gong Y; Handberg EM; Elgendy IY; Bavry AA; Cooper-DeHoff RM; Pepine CJ
    J Hypertens; 2018 Feb; 36(2):419-427. PubMed ID: 28938338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.
    Yusuf S; Pfeffer MA; Swedberg K; Granger CB; Held P; McMurray JJ; Michelson EL; Olofsson B; Ostergren J;
    Lancet; 2003 Sep; 362(9386):777-81. PubMed ID: 13678871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of Central Blood Pressure to Hypertensive Target Organ Damages During Antihypertensive Treatment: The J-TOP Study.
    Shimizu M; Hoshide S; Ishikawa J; Yano Y; Eguchi K; Kario K
    Am J Hypertens; 2015 Aug; 28(8):980-6. PubMed ID: 25548141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between systolic blood pressure and preserved or reduced ejection fraction at admission in patients hospitalized for acute heart failure syndromes.
    Kajimoto K; Sato N; Sakata Y; Takano T;
    Int J Cardiol; 2013 Oct; 168(5):4790-5. PubMed ID: 23962780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationships between blood pressure lowering therapy and cardiovascular events in hypertensive patients with coronary artery disease and type 2 diabetes mellitus: The HIJ-CREATE sub-study.
    Kamishima K; Ogawa H; Jujo K; Yamaguchi J; Hagiwara N
    Diabetes Res Clin Pract; 2019 Mar; 149():69-77. PubMed ID: 30735770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Candesartan-based therapy and risk of cancer in patients with systemic hypertension (Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] substudy).
    Sugiura R; Ogawa H; Oka T; Koyanagi R; Hagiwara N;
    Am J Cardiol; 2012 Feb; 109(4):576-80. PubMed ID: 22100194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and application of normal limits for left ventricular ejection fraction and volume measurements from 99mTc-sestamibi myocardial perfusion gates SPECT.
    Rozanski A; Nichols K; Yao SS; Malholtra S; Cohen R; DePuey EG
    J Nucl Med; 2000 Sep; 41(9):1445-50. PubMed ID: 10994721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program.
    Meredith PA; Ostergren J; Anand I; Puu M; Solomon SD; Michelson EL; Olofsson B; Granger CB; Yusuf S; Swedberg K; Pfeffer MA; McMurray JJ
    J Am Coll Cardiol; 2008 Dec; 52(24):2000-7. PubMed ID: 19055992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practitioner's trial on the efficacy of antihypertensive treatment in elderly patients with hypertension II (PATE-hypertension II study) in Japan.
    Ogihara T; Matsuoka H; Rakugi H
    Geriatr Gerontol Int; 2011 Oct; 11(4):414-21. PubMed ID: 21410854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversibility of left ventricular mechanical dysfunction in patients with hypertensive heart disease.
    Cheng S; Shah AM; Albisu JP; Desai AS; Hilkert RJ; Izzo J; Oparil S; Pitt B; Solomon SD
    J Hypertens; 2014 Dec; 32(12):2479-86; discussion 2486-7. PubMed ID: 25232755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.